机构：[1]Beijing Tongren Eye Center, Beijing Institute of Ophthalmology, Beijing Tongren Hospital, Capital Medical University and Beijing Ophthalmology and Visual Sciences Key Laboratory, Beijing, China,首都医科大学附属北京同仁医院首都医科大学附属同仁医院[2]Department of Ophthalmology, The 4th People's Hospital of Shenyang, Shenyang, China,[3]Department of Ophthalmology, The Forth Affiliated Hospital of Medical School, Shenyang, China,[4]Department of Ophthalmology, First Hospital of Jilin University, Jilin, China,[5]Department of Refractive and Corneal Diseases, Eye Center of Tianjin Medical University, Tianjin, China,[6]Department of Ophthalmology, Peking University First Hospital, Beijing, China[7]Department of Ophthalmology, The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, China,浙江大学医学院附属第一医院[8]Eye Center, The Second Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, China,[9]Department of Ophthalmology, Xi'an No. 1 Hospital, Xi’an, China,[10]Department of Ophthalmology, Nanjing First Hospital, Nanjing, China,[11]Department of Ophthalmology, Eye and Ent Hospital of Fudan University, Shanghai, China,[12]Department of Ophthalmology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China,[13]Department of Ophthalmology, Second People's Hospital of Yunnan, Kunming, China,[14]Department of Ophthalmology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning City, China,[15]Department of Ocular Surface Diseases, Jinan Second People's Hospital, Jinan, China,[16]Department of Ophthalmology, Affiliated Hospital of Chengde Medical University, Chengde, China,[17]Department of Corneal Diseases, The Affiliated Hospital of Nanjing Medical University, Nanjing, China,[18]Department of Corneal Diseases, Eye Hospital, WMU, Zhejiang EYE Hospital, Hangzhou, China,[19]Department of Keratopathy and Ocular Surface Diseases, Shenzhen Eye Hospital, Shenzhen, China,深圳市康宁医院深圳医学信息中心[20]Department of Cataract Division, Joint Shantou International Eye Center (JSIEC), Shantou University and The Chinese University of Hong Kong, Shantou, China,[21]Department of Ophthalmology, The Third People's Hospital of Dalian, Dalian, China,[22]Department of Ophthalmology, Xuanwu Hospital of Capital Medical University, Beijing, China,外科系统眼科首都医科大学宣武医院[23]Department of Ophthalmology, The Second Hospital of Central South University, Changsha, China,[24]Department of Ophthalmology, The People's Hospital of Leqing, Wenzhou, China,[25]Department of Ophthalmology, Daqing Ophthalmologic Hospital, Daqing, China,[26]Department of Corneal Diseases, Zhongshan Ophthalmic Center (ZOC) of Sun YAT-Sen University, Guangzhou, China,[27]Department of Corneal Diseases, Qingdao Eye Hospital, Qingdao, China,[28]Department of Ophthalmology, Guangzhou First People's Hospital, Guangzhou, China,[29]Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, China,四川大学华西医院[30]Department of Ophthalmology, Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China华中科技大学同济医学院附属同济医院
IntroductionThe efficacy and safety of 3% diquafosol sodium eye drops in Chinese patients with dry eye in the real-world setting remains unclear. Methods3099 patients with dry eye symptoms were screened according to Asia Dry Eye Society latest recommendation. Among them, 3000 patients were enrolled for a phase IV study. We followed up with multiple clinical characteristics including corneal fluorescein staining, tear break up time, Schirmer's tests, visual acuity, intraocular pressure, and others. The follow ups were performed at baseline, 2 weeks and 4 weeks after treatment. ResultsBased on the results of corneal fluorescein staining and tear break up time, all age and gender subgroups exhibited obvious alleviation of the symptoms among the patients with dry eye, and the data in elderly group showed the most significant alleviation. All the adverse drug reactions (ADRs, 6.17%) were recorded, among which 6% local ocular ADRs were included. Meanwhile, mild ADRs (91.8%) accounted for the most. Most of the ADRs (89.75%) got a quick and full recovery, with an average time at 15.6 days. 1.37% of patients dropped out of the study due to ADRs. DiscussionThe use of 3% diquafosol sodium eye drop is effective and safe in the treatment of dry eye, with a low incidence of ADRs showing mild symptoms. This trial was registered at Chinese Clinical Trial Registry ID: ChiCTR1900021999 (Registration Date: 19/03/2019).
第一作者机构：[1]Beijing Tongren Eye Center, Beijing Institute of Ophthalmology, Beijing Tongren Hospital, Capital Medical University and Beijing Ophthalmology and Visual Sciences Key Laboratory, Beijing, China,
通讯作者：
推荐引用方式(GB/T 7714)：
Wenying Wang,Xiaonan Sun,Jiangyue Zhao,et al.3% diquafosol sodium eye drops in Chinese patients with dry eye: a phase IV study[J].FRONTIERS IN MEDICINE.2023,10:doi:10.3389/fmed.2023.1089613.
APA：
Wenying Wang,Xiaonan Sun,Jiangyue Zhao,Jilong Hao,Shaozhen Zhao...&Zhiqiang Pan.(2023).3% diquafosol sodium eye drops in Chinese patients with dry eye: a phase IV study.FRONTIERS IN MEDICINE,10,
MLA：
Wenying Wang,et al."3% diquafosol sodium eye drops in Chinese patients with dry eye: a phase IV study".FRONTIERS IN MEDICINE 10.(2023)
